Cite
Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984).
MLA
Biesma, B., et al. “Docetaxel and Cisplatin as Induction Chemotherapy in Patients with Pathologically-Proven Stage IIIA N2 Non-Small Cell Lung Cancer: A Phase II Study of the European Organization for Research and Treatment of Cancer (EORTC 08984).” European Journal of Cancer (Oxford, England : 1990), vol. 42, no. 10, July 2006, pp. 1399–406. EBSCOhost, https://doi.org/10.1016/j.ejca.2006.01.049.
APA
Biesma, B., Manegold, C., Smit, H. J. M., Willems, L., Legrand, C., Passioukov, A., van Meerbeeck, J. P., & Giaccone, G. (2006). Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984). European Journal of Cancer (Oxford, England : 1990), 42(10), 1399–1406. https://doi.org/10.1016/j.ejca.2006.01.049
Chicago
Biesma, B, C Manegold, H J M Smit, L Willems, C Legrand, A Passioukov, J P van Meerbeeck, and G Giaccone. 2006. “Docetaxel and Cisplatin as Induction Chemotherapy in Patients with Pathologically-Proven Stage IIIA N2 Non-Small Cell Lung Cancer: A Phase II Study of the European Organization for Research and Treatment of Cancer (EORTC 08984).” European Journal of Cancer (Oxford, England : 1990) 42 (10): 1399–1406. doi:10.1016/j.ejca.2006.01.049.